Dore F, Bonfigli S, Gaviano E, Pardini S, Longinotti M
Istituto di Ematologia, Università di Sassari, Italy.
Haematologica. 1996 Jan-Feb;81(1):37-9.
In this study we determined the levels of circulating soluble transferrin receptor (sTfR) in six untransfused and two transfused patients affected by beta-thalassemia intermedia during low-dose rHuEPO administration. While the majority of the untransfused patients showed a temporary increment during the first month of treatment, a higher and enduring increase in sTfR concentration was observed in the two transfused patients until rHuEPO was discontinued. The transfused patients showed a significant increase in the reticulocyte index together with the rise in sTfR and an improvement of the anemia, as evidenced by the decrease in their transfusional requirement. These data suggest that basal erythropoietic activity is one of the main causes of differences in responsiveness to low doses of rHuEPO given in thalassemia intermedia.
在本研究中，我们测定了6例未经输血和2例经输血的中间型β地中海贫血患者在低剂量重组人促红细胞生成素（rHuEPO）给药期间循环可溶性转铁蛋白受体（sTfR）的水平。虽然大多数未经输血的患者在治疗的第一个月出现了短暂升高，但在2例经输血的患者中观察到sTfR浓度有更高且持续的升高，直至rHuEPO停药。经输血的患者网织红细胞指数显著增加，同时sTfR升高，贫血得到改善，这可通过其输血需求的减少得到证明。这些数据表明，基础红细胞生成活性是中间型地中海贫血患者对低剂量rHuEPO反应性差异的主要原因之一。
